Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Advertising, Marketing & Sales FDA Regulation

Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says

  • Analysis

Executive Summary

Office of Prescription Drug Promotion is focused on most egregious issues where human safety is at stake; CDER's Woodcock also says that First Amendment issues are affecting enforcement.
Table

View full table

Advertisement

Related Content

Pink Sheet
US FDA Advertising Citations Remain Rare In 2018
Pink Sheet
Ascend’s EstroGel Promotion Misrepresents Efficacy Compared To Other Products, US FDA Says
Pink Sheet
FDA's Promotional Reviews Decline, But Says It's Only Part Of Job
Pink Sheet
FDA Advertising Enforcement Highlighted By HHS Amid Drop In Citations
Pink Sheet
Off-Label Promotion Decisions Likely Made Case-by-Case, US FDA Official Says
Pink Sheet
First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates
Pink Sheet
Industry Communications With Payors: US FDA Okays Info On Investigational Drugs
Pink Sheet
Industry's Off-Label Hearing Priorities Taking Shape
Pink Sheet
Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement
Pink Sheet
Internet Searching May Get ‘Riskier’ For Patients After FDA Citations

Topics

Related Companies

Advertisement
Tags:
Advertising, Marketing & Sales FDA Regulation
UsernamePublicRestriction

Register

PS123921

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By